OTCMKTS:NWBO - Northwest Biotherapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2330 -0.01 (-4.12 %) (As of 01/18/2019 04:00 PM ET)Previous Close$0.2330Today's Range$0.2301 - $0.244552-Week Range$0.17 - $0.3495Volume344,589 shsAverage Volume749,252 shsMarket Capitalization$125.79 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Receive NWBO News and Ratings via Email Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CUSIPN/A Webwww.nwbio.com Phone240-497-9024Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$330,000.00 Price / Sales370.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-1.17Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-73,140,000.00 Net Margins-6,258.93% Return on EquityN/A Return on Assets-157.85%Miscellaneous Employees16 Outstanding Shares524,340,000Market Cap$125.79 million OptionableNot Optionable Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions What is Northwest Biotherapeutics' stock symbol? Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO." How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) released its earnings results on Friday, November, 16th. The biotechnology company reported ($0.03) earnings per share for the quarter. The biotechnology company had revenue of $0.45 million for the quarter. View Northwest Biotherapeutics' Earnings History. When is Northwest Biotherapeutics' next earnings date? Northwest Biotherapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 15th 2019. View Earnings Estimates for Northwest Biotherapeutics. What price target have analysts set for NWBO? 0 Wall Street analysts have issued 12-month target prices for Northwest Biotherapeutics' shares. Their forecasts range from $0.23 to $0.23. On average, they expect Northwest Biotherapeutics' share price to reach $0.23 in the next twelve months. This suggests that the stock has a possible downside of 1.3%. View Analyst Price Targets for Northwest Biotherapeutics. Has Northwest Biotherapeutics been receiving favorable news coverage? News stories about NWBO stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Northwest Biotherapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. Who are some of Northwest Biotherapeutics' key competitors? Some companies that are related to Northwest Biotherapeutics include Obseva (OBSV), Theratechnologies (THERF), BioSpecifics Technologies (BSTC), Prothena (PRTA), Forty Seven (FTSV), Innate Pharma (IPHYF), Odonate Therapeutics (ODT), Corium International (CORI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Eidos Therapeutics (EIDX), Akorn (AKRX), Clementia Pharmaceuticals (CMTA), Evolus (EOLS) and Corbus Pharmaceuticals (CRBP). Who are Northwest Biotherapeutics' key executives? Northwest Biotherapeutics' management team includes the folowing people: Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 62)Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 73)Dr. Marnix L. Bosch Ph.D., MBA, Chief Technical Officer (Age 59)Mr. Leslie J. Goldman, Sr. VP of Bus. Devel. (Age 73)Ms. Susan Goldman, Director of Patient Affairs How do I buy shares of Northwest Biotherapeutics? Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Northwest Biotherapeutics' stock price today? One share of NWBO stock can currently be purchased for approximately $0.2330. How big of a company is Northwest Biotherapeutics? Northwest Biotherapeutics has a market capitalization of $125.79 million and generates $330,000.00 in revenue each year. Northwest Biotherapeutics employs 16 workers across the globe. What is Northwest Biotherapeutics' official website? The official website for Northwest Biotherapeutics is http://www.nwbio.com. How can I contact Northwest Biotherapeutics? Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected] MarketBeat Community Rating for Northwest Biotherapeutics (OTCMKTS NWBO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 97 (Vote Outperform)Underperform Votes: 83 (Vote Underperform)Total Votes: 180MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe NWBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWBO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?